section name header

Indications ⬇

REMS


Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Takhzyro

Action ⬆ ⬇

  • Acts as a selective, reversible inhibitor of kallikrein, thereby inhibiting its action in initiating bradykinin production, part of the cascade of events in hereditary angioedema.
Therapeutic effects:
  • Reduction in number of hereditary angioedema attacks.

Classifications ⬆ ⬇

Therapeutic Classification: antiangioedema agents

Pharmacologic Classification: kallikrein inhibitors, monoclonal antibodies

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following SUBQ administration.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Unknown.

Half-Life: 14–15 days.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTEONSETPEAKDURATION
SUBQunknown4–5 daysunknown



Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆

LAN-a-DEL-ue-mab